

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C08F 283/00, C03C 4/00 C03C 15/00	A1	(11) International Publication Number: WO 93/10162 (43) International Publication Date: 27 May 1993 (27.05.93)		
<table border="0" style="width: 100%;"><tr><td style="width: 50%; vertical-align: top;">(21) International Application Number: PCT/US92/10113 (22) International Filing Date: 17 November 1992 (17.11.92) (30) Priority data: 07/794,910 20 November 1991 (20.11.91) US (60) Parent Application or Grant (63) Related by Continuation US 07/794,910 (CON) Filed on 20 November 1991 (20.11.91) (71) Applicant (for all designated States except US): CPG, INC. [US/US]; 32 Pier Lane West, Fairfield, NJ 07006 (US).</td><td style="width: 50%; vertical-align: top;">(72) Inventor; and (75) Inventor/Applicant (for US only): WONG, Yuan, N. [US/ US]; 56 Intervale Road, Boonton, NJ 07005 (US). (74) Agent: IRONS, Edward, S.; 919 - 18th Street, N.W., Suite 800, Washington, DC 20006 (US). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). Published <i>With international search report.</i> <i>With amended claims.</i></td></tr></table>			(21) International Application Number: PCT/US92/10113 (22) International Filing Date: 17 November 1992 (17.11.92) (30) Priority data: 07/794,910 20 November 1991 (20.11.91) US (60) Parent Application or Grant (63) Related by Continuation US 07/794,910 (CON) Filed on 20 November 1991 (20.11.91) (71) Applicant (for all designated States except US): CPG, INC. [US/US]; 32 Pier Lane West, Fairfield, NJ 07006 (US).	(72) Inventor; and (75) Inventor/Applicant (for US only): WONG, Yuan, N. [US/ US]; 56 Intervale Road, Boonton, NJ 07005 (US). (74) Agent: IRONS, Edward, S.; 919 - 18th Street, N.W., Suite 800, Washington, DC 20006 (US). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). Published <i>With international search report.</i> <i>With amended claims.</i>
(21) International Application Number: PCT/US92/10113 (22) International Filing Date: 17 November 1992 (17.11.92) (30) Priority data: 07/794,910 20 November 1991 (20.11.91) US (60) Parent Application or Grant (63) Related by Continuation US 07/794,910 (CON) Filed on 20 November 1991 (20.11.91) (71) Applicant (for all designated States except US): CPG, INC. [US/US]; 32 Pier Lane West, Fairfield, NJ 07006 (US).	(72) Inventor; and (75) Inventor/Applicant (for US only): WONG, Yuan, N. [US/ US]; 56 Intervale Road, Boonton, NJ 07005 (US). (74) Agent: IRONS, Edward, S.; 919 - 18th Street, N.W., Suite 800, Washington, DC 20006 (US). (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). Published <i>With international search report.</i> <i>With amended claims.</i>			
(54) Title: PRODUCTION AND USE OF MAGNETIC POROUS INORGANIC MATERIALS (57) Abstract Magnetic porous inorganic siliceous materials having a particle size of about 1 to about 200 microns useful as solid supports in various chromatography, immunoassays, synthesis and other separation and purification procedures as disclosed.				

ATTORNEY DOCKET NUMBER.: 1803-337

SERIAL NUMBER.: 09/756,743

REFERENCE: A113

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

PRODUCTION AND USE OF
MAGNETIC POROUS INORGANIC MATERIALS

This application is a continuation of United States application Serial No. 07/794,910 filed 20 November 1991.

FIELD OF INVENTION

This invention provides porous inorganic, magnetic materials useful in biochemical synthesis, assay, purification and separation procedures. More particularly the invention relates to magnetic siliceous inorganic materials such as controlled pore glass (CPG), porous silica gel, and porous ceramic products, to methods for the preparation of such products, and to various uses for such products. The invention relates to the surface modification of such products by, e.g., physically adsorbed or chemically immobilized biological molecules, and to practical applications thereof.

BACKGROUND OF THE INVENTION

Porous inorganic siliceous materials including glass, ceramics, and silica gel are used as solid supports in chromatography, immunoassays, synthesis and other separation and purification procedures.

Gravitational and centrifuged separation of such porous materials from the surrounding medium when used in batch procedures such as immunoassays, is inefficient and time consuming. Centrifugal separations also require expensive and energy consuming apparatus.

Separation of magnetic solid supports is relatively easy and simple, especially for multiple, small aliquots of the kind frequently encountered in sample preparation and immunoassay procedures. Agitation of magnetic solid supports is readily accomplished by on and off switching of magnetic fields located at opposite sides of a container or simply shaken by hand. Non-porous metal oxide magnetic particles and magnetic polystyrene beads lack surface area necessary to provide high binding capacity.

-2-

Although there are quite a number of magnetic materials commercially available or reported in the literature, such as: iron oxide particles of U.S. patents 4,554,088 and 3,917,538; nickel oxide particles in Biotec. and Bioengr. XIX:101-124 (1977); agarose-polyaldehyde bead containing magnetic particles of U.S. patent 4,732,811. Commercial products such as: "DYNABEADS" (magnetic polystyrene bead); "MAGNOGEL 44" (magnetic polyacrylamide-agarose); "ENZACRY" (poly-m-diaminobenzene of iron oxide) reported in Clin. Chim. Acta. 69:387-396 (1976). Other types of magnetical particles reported in the literature include: cellulose containing ferric oxide, Clin. Chem. 26:1281-1284 (1980) and albumin magnetic microspheres, Ovadia, et al. J. Immunol. Methods 53:109-122 (1982).

SUMMARY OF THE INVENTION

This invention provides a novel and simple method for making porous inorganic magnetic materials including any glass, silica gel or alumina, useful, e.g., in the separation of biochemical moieties or biological molecules or fragments thereof from a surrounding medium, in the synthesis of peptides and oligonucleotides, in the purification of mRNA or poly (dA) directly after synthesis and in DNA assay procedures in various immunoassay procedures for enzyme immobilization and in sample preparation.

The magnetic products of the invention have a pore diameter of from about 60 to about 6,000 Angstroms (A); preferably between about 300A to about 5,000A. Specific pore volume, which is proportional to the surface area for a given pore size is from about 0.5 to about 2.5 cc/gm, preferably from about 0.75 to about 1.5 cc/gm. Particle size is from about 1 to about 200 microns, preferably from about 5 to about 50 microns.

-3-

This invention provides both ferromagnetic materials and superparamagnetic materials. The latter are preferred to preclude magnetic aggregation and to facilitate redispersion upon removal of a magnetic field.

This invention also includes porous inorganic magnetic materials, preferably siliceous materials, surface modified to provide functional groups such as amino, hydroxyl, carboxyl, epoxy, aldehyde, sulfhydryl, phenyl or long chain alkyl groups to facilitate the chemical and/or physical attachment of biological molecules and other moieties, e.g., enzymes, antibodies, oligopeptides, oligonucleotides, oligosaccharides or cells. Surface modification to create such functionality may be accomplished by coating with organic silanes. See, e.g., Bonded Stationary Phases in Chromatography, ed. by E. Grushka (1974). Alternate methods for providing derivatized or functional group containing surfaces on the magnetic products of this invention include U.S. patents 3,983,299 and 4,554,088.

None of the prior art magnetic porous inorganic particles known to applicant have the same practical range of pore diameter, narrow pore diameter distribution, high pore volume, high surface area, surface modification versatility, solvent system compatibility and simplicity of production as the products of this invention.

DEFINITIONS

The following definitions apply to this application:

The term "magnetic porous inorganic materials" is defined as any porous siliceous inorganic materials such as porous glass, porous silica gel and porous alumina, etc., which comprises magnetic materials either through physical adsorption or chemical binding.

The term "magnetic material" is defined as a transition metal oxide having ferrosipinel structure and comprising trivalent and divalent cations of the same or different transitional metals, for example, iron oxide Fe_3O_4 .

The term "colloidal magnetic particles" is defined as finely divided magnetic materials of submicron size, usually 50-250 Angstrom. Such particles may be present in combination with a carrier liquid and a surfactant material and may remain dispersed throughout a carrier liquid medium.

The term "superparamagnetism" is defined as the magnetic behavior exhibited by the magnetic materials, which respond to a magnetic field without resultant permanent magnetization.

The term "solid phase sandwich type radioimmunoassay (RIA)" refers to an immunoassay in which a solid phase is first immobilized with an antibody (or antigen) and is then used to bind the targeted antigen (or antibody) in a sample. A second antibody (or antigen) labelled with radioactive materials is then added to bind the antigen (or antibody) serving as a signal for the presence of the target antigen (or antibody). The immunocomplex formed on the solid phase would be like Ab-Ag-Ab^* (or Ag-Ab-Ag^*), hence, a sandwich type immunoassay.

DETAILED DESCRIPTION OF THE INVENTION

The porous inorganic magnetic materials of the invention are produced by adding magnetic metallic particles such as iron oxide, preferably as an aqueous colloidal suspension to an aqueous slurry of CPG, siliceous material such as silica gel, or alumina, agitation of the mixture, removal of excess magnetic particles, and drying the product. Aqueous colloidal iron oxide is preferred.

The CPG, silica gel or alumina used in the process is selected to have a pore diameter, pore volume and particle size to provide a final porous magnetic product of the desired physical characteristics. Combination with, e.g., iron oxide, may reduce original pore volume by about 5% to about 15%.

Controlled pore glass useful in this invention is commercially available in a range of pore dimensions from CPG, Inc., 32 Pier Lane West, Fairfield, New Jersey. The production of controlled pore glass is described in U.S. patents 3,549,524 and 3,758,284.

Colloidal magnetic particles useful in the invention constitute from about 2% to 15% by volume of magnetic particles in liquid, preferably water, suspension medium. Colloidal iron oxide is commercially available as "Ferrofluid" (trademark) from Ferrofluidics Corp., 40 Siman Street, Nashua, New Hampshire. Ferrofluids containing from about 1% to about 6% of iron oxide in water or organic phase such as perfluorinated polyether or diester are useful in the practice of the invention. The production of ferrofluid is described in U.S. Patents 3,531,413 and 3,917,538.

Agitation of the mixture of porous inorganic material and colloidal magnetic particles is appropriately accomplished by shaking or by a non-metallic mixer at room temperature for a time period of from about 3 to 96 hours. Discoloration of, e.g., CPG, indicates adsorption or lodging of the colloidal magnetic particles within the pores of the inorganic material.

Removal of unbound colloidal magnetic particles may be accomplished by washing with water followed by polar liquids. An appropriate washing sequence is water, 1.5M aqueous sodium chloride, acetone and methanol. Each wash step is continued until the supernatant is clear.

The final, washed, magnetic particles are filtered and dried, e.g., overnight at 90°C or at 120°C for one hour or vacuum dried for six hours. Depending on the pore diameter, the dry magnetic porous particles appear light to dark brown in color and respond to a magnetic field. In general, materials of relatively small pore diameter which have a higher specific surface area adsorb more colloidal magnetic particles and, hence, exhibit stronger magnetic properties than materials of larger pore diameter.

To provide functional groups for the binding of biological moieties including cells and biomolecules. The magnetic porous particles may then be subjected to surface modification such as silanization. See, e.g., Grusha, supra and U.S. patents 3,383,299 and 4,554,088. It also secures immobilization of the magnetic particle in the inorganic material pores.

A general formula for the silicone compounds useful for silanization is: $R-Si-X$, where R represents an organic moiety with a terminal functional group such as an amino, hydroxyl, epoxy, aldehyde, sulfhydryl, phenyl, long chain alkyl or other group that will chemically react or physically absorb with the biological molecules and X may be a mono-, di- or trialkoxy or halide group which will react with the silanol groups on the surface of the inorganic material. The degree of silanization can be demonstrated through quantitative analysis of the respective functional groups.

-7-

The preferred colloidal magnetic particles for use in this invention are superparamagnetic metal oxide. The size of the colloidal particles may range from 1 to 100 nm, preferably 5 to 50 nm (30 to 500 Angstroms (A)). Other superparamagnetic colloidal solutions are described in U.S. Patents 3,215,572 and 4,554,088.

EXAMPLE I

Preparation of Magnetic Porous Inorganic Material With Ferrofluid Colloidal Particles

5 gm of controlled pore glass (CPG, pore diameter of 3000 Angstrom, 37-77 microns) was added to a 70 ml container containing 50 ml of deionized water. To the glass slurry, 1 ml of Ferrofluid colloidal iron oxide (Ferrofluidics Corp.) was added. The Ferrofluid contained 1 to 3% by volume superparamagnetic 100A iron oxide particles in an aqueous medium. The container was placed in the shaker and gently shaken for 24 hours. The glass particles turned into dark brown color. Excessive Ferrofluid was decanted off after the glass settling down. After five washes with water, one wash with 1.5 M NaCl solution, three more water washes and three more methanol washes, the magnetic controlled porous glass (magnetic CPG) was then filtered and dried at 90°C for eight hours. The final product was attracted by laboratory permanent magnet.

Physical characteristics of the magnetic controlled porous glass (magnetic CPG) product were checked by microscopic examination. Pore morphology was determined by porosimeter and surface area analyzer. Under the microscope, the appearance of the magnetic CPG was the same as the regular porous glass except that the magnetic CPG particle was of a uniform brown color. The porosity data for both

-8-

before and after coating magnetic particles are listed in Table I. Specific pore volume was decreased as expected, because part of the pore volume was occupied by the colloidal iron oxide particles. The increase in the surface area is due to the existence of colloidal particles.

Table I

Porosity Data For Glass Particles Before and After Coating with Magnetic Colloidal Particles

	Before Coating	After Coating
Mean pore dia. (A)	3000	3000
Specific pore vol. (cc/gm)	0.89	0.84
Pore diam. distribution (%)	8.4	6.9
Surface area (M ² /gm)	7.4	8.97
Lot No.	11C24	081783-2

EXAMPLE II

Preparation of Magnetic Silica Gel With Colloidal Magnetic Particles (Magnetic Silica Gel)

5 grams of Daisogel, a silica gel product of Daiso Co., Inc., 10-5, Edobori 1-Chome Nishi-Ku, Osaka, Japan, having pore diameter of 1000 Angstrom, 5 micron spherical bead was slurried in a 70 ml bottle containing 50 ml of tetrahydrofuran. To the silica gel slurry, 1 ml of ferrofluid colloidal iron oxide was added. The ferrofluid contained 3 to 6% by volume of superparamagnetic 100 A iron oxide particles in organic base medium. The container was placed in the shaker and shaken for 24 hours at room temperature. At the end of mixing time, the excess

-9-

solution was decanted off. The silica gel was then washed with 3 X 10 ml of tetrahydrofuran, 3 X 10 ml of ethyl acetate, 5 X 10 ml of methanol and finally another 5 X 10 ml of deionized water. During each washing cycle, a permanent magnet was used to accelerate the settling down of the magnetic silica gel. The magnetic silica gel was then dried at 120°C for 1 hour. The porosity data for both uncoated and magnetic colloidal particle coated Daisogel are listed in Table II.

Table II

Porosity Data for Silica Gel Particles
Before and After Coating with Colloidal Iron Oxide

	Before Coating	After Coating
Mean pore diameter (Angstrom)	688	685
Specific pore volume (cc/gm)	.95	.85
Pore diam. distribution (%)	27.3	24.7
Surface area (M ² /gm)	67.1	60.6
Lot No.	DS-GEL05	MSIL1005

EXAMPLE III

Preparation of Magnetic Porous Inorganic
Materials With Colloidal Iron Oxide Particles

Colloidal iron oxide was prepared by the method of U.S. patent 4,554,088 with some modification: A 20 ml of 2:1 molar ratio of FeCl₂/FeCl₃, solution was mixed with equal volume of 4.5 M sodium hydroxide to form a crystalline precipitate of superparamagnetic iron oxide, having a particle size diameter of 0.1 to 1.5 microns. For the purposes of this invention,

-10-

such particle size was too large to produce magnetic porous particles. To obtain the appropriate colloidal size of iron oxide particles, the concentration of ferrous/ferric chloride was diluted at least 10 fold, the mixing of iron chloride solution and sodium hydroxide was done in a ultrasonic bath for at least two hours, and the pH of the precipitate solution was adjusted to about 7.5. The particle size was monitored by microscopic observation or by light scattering technique. Aggregation, if any, found among the colloidal particles was washed away in the course of the porous material coating procedure. The final iron oxide particle size was about 200 Angstrom to about 500 Angstrom.

2 gm of controlled pore glass (CPG, pore diameter of 1000 Angstrom, 77-125 microns (CPG, Inc.)) was mixed with 10 ml colloidal iron oxide (50 vol. % precipitate). The slurry was shaken gently in the shaker for 24 hours. Excessive colloidal iron oxide was decanted off, and glass slurry was exhaustively washed with water until the supernate became clear. The glass was then washed with methanol, filtered and dried in the oven at 90°C for eight hours. The final product was brown in color and attracted by a permanent magnet.

EXAMPLE IV

Preparation of Magnetic Amino Controlled Pore Glass (Magnetic Amino CPG)

The product of Example I was further dried under vacuum at room temperature for two hours. 5 gm of the dried magnetic CPG was placed in a three neck round bottom flask. 150 ml of 10% gamma-aminopropyltrimethoxysilane in dry toluene was

-11-

added to the flask. The slurry was gently stirred under refluxing condition for 24 hours. The glass was then washed with methanol for five times to remove excessive silane. The settling process could be sped up by placing a circular magnet under the container. The glass was then filtered and baked in the oven at 90°C for eight hours. The magnetic amino glass (magnetic amino CPG) was quantified by titration and found to have 35.5 micromole amino groups per gram of solid.

EXAMPLE V

Preparation of Magnetic Epoxide Controlled Pore Glass (Magnetic Epoxide CPG)

5 gm of dried magnetic CPG prepared as described by Example I was placed in a three neck round bottom flask. 150 ml of 10% 3-glycidoxypropyltrimethoxy-silane in dry toluene was added to the flask. The slurry was gently stirred under refluxing condition for 24 hours. The magnetic CPG was then washed with methanol and acetone to remove excessive silane. The magnetic CPG glass was then filtered and baked in the oven at 100°C for 16 hours. The epoxide group was quantified by titration and found to have 42 micromoles per gram of solid.

EXAMPLE VI

Coupling of Anti-HBs. γ to Magnetic Amino-Controlled Pore Glass (Magnetic Amino-CPG)

One gram of magnetic amino glass (magnetic amino-CPG) prepared from Example IV was added to a bottle containing 30 ml of 10% aqueous glutaraldehyde at pH-7.0. The slurry was shaken gently in the shaker for one half hour at room temperature. 30 mg of sodium borohydride was then added and the slurry was then shaken in an ice-water bath for three hours.

-12-

At the end of the reaction, the glass was washed with phosphate buffer thoroughly. The settling of the glass particles was accelerated by using a magnetic field. The amino groups on the surface of the glass were thus converted to aldehyde moieties.

9.9 ml (1 mg/ml protein conc.) of crude goat anti-human hepatitis B surface antigen (anti-HBsAg) antibody solution (Electro-Nucleonics Laboratory, Inc.) was added to 1 gm of magnetic aldehyde glass and 12 mg of sodium borohydride. 0.1 M sodium carbonate of pH=9.5 was used to adjust the pH of the mixture to 8.5. The slurry was shaken in the refrigerator for 24 hours. The antibody coupled particles was then washed three times with 0.1 M sodium phosphate buffer, pH=7.5 (five times). To block any active sites from residue silanol, amino or aldehyde groups, 5 ml (2 mg/ml) human serum albumin solution was treated with the magnetic antibody coated glass particles for three more hours. The magnetic antibody coated glass (magnetic antibody-CPG) slurry was then washed with phosphate buffered saline (PBS) three time, 1M NaCl once, and back to PBS three more times. The particles were then stored in the refrigerator for use in immunoassay procedures.

EXAMPLE VII

Magnetic Antibody Coated Controlled
Pore Glass (Magnetic Antibody-CPG)
For Sandwich Type Radioimmunoassay (RIA)
For Human Hepatitis B Surface Antigen HBsAg

200 microliter of four negative and three positive serum standards containing deactivated human hepatitis B surface antigen were applied to each Riasure assay tube ("Riasure" is the trademark for radioimmunoassay for human hepatitis B surface antigen, produced by Electro-Nucleonics Laboratory, Inc.) containing one tablet form of CPG powder (which

-13-

disintegrated back into powder form in the serum sample) or 10 microliter of the magnetic antibody CPG slurry, prepared from Example VI in working buffer (1:1 vol. %). After one hour of incubation at 25°C, both glass slurries were washed five times with supplied phosphate buffer saline (PBS). The washing cycle for non-magnetic glass particles were 60 seconds stirring and 90 seconds settling; for magnetic particle, the washing cycles had been cut down to 60 seconds stirring and 20 seconds of settling with the help of an external magnetic field on the side. After five washing cycles, 100 microliter of radioactive iodine (I^{125}) labelled goat anti-hepatitis B surface antibody (I^{125} anti-HBsAg) was then added to each assay tube. After another hour incubation at 25°C, the glass particles were again subjected to five PBS (phosphate buffered saline) washing cycles prior to radiation count. The results obtained from RIA are presented in the following Table III.

Table III

Radioimmunoassay For Hepatitis B Surface
Antigen With Regular And Magnetic Glass Particles

Count Per Minute (CPM)		
<u>Samples</u>	<u>Regular CPG</u>	<u>Magnetic CPG</u>
Negative	169	200
Negative	142	271
Negative	196	347
Negative	161	233
Positive	25589	39026
Positive	22551	33243
Positive	25909	36257
Ratio of P/N	147.8	137.5

EXAMPLE VIII

Preparation of Magnetic Nucleoside CPG

Magnetic dT-CPG is prepared to demonstrate the production of magnetic nucleoside CPGs.

Deoxythymidine (dT) is used in this example. dA, dC and dG CPG products are produced in like manner.

5 gram of dried magnetic epoxide CPG prepared in Example V was placed in a 100 ml round bottom flask. To the dried glass powder, 5 gram of 1,6-hexanediamine in 50 ml of dried methanol was added. The slurry was stirred gently at room temperature for three hours. At the end of the reaction, the glass was washed with methanol, 0.05 M sodium acetate buffer of pH 5.5, then deionized water, then final methanol wash before it was filtered and dried. The magnetic long chain amino glass (Magnetic Long Chain Amino CPG) was found to have 35 micromole of primary amine per gram of solid. One gram of this magnetic long chain amino glass, 160 mg of DMTr-deoxythymidine succinic acid, 0.160 ml 1,3-diisopropylcarbodiimide, 2.2 mg 4-dimethylaminopyridine, 1 ml pyridine and 4 ml N,N-dimethylformamide were mixed together in a 8 ml amber vial. The vial was placed on an orbital shaker for shaking 24 hours at room temperature. At the end of the reaction, the glass was capped with 0.1 ml acetic anhydride for three hours followed by quenching the excessive anhydride with 0.2 ml dried methanol in ice-bath for another three hours. The magnetic DMTr-thymidine glass (magnetic DMTr-dT-CPG) was then washed with N,N-dimethylformamide, methanol and dichloromethane before subjected to vacuum drying. The glass was quantified by cleaving the DMTr (dimethoxytrityl-) moiety from the glass with 3% p-toluenesulfonic acid in acetonitrile and measure its absorbance at 504 nm. The DMTr groups were found to be 23 micromoles per gram of solid.

-15-

EXAMPLE IX

Synthesis of 20-Mer Oligonucleotide
With Magnetic DMTr-deoxythymidine
CPG (Magnetic DMTr-dT CPG)

10 mg of the magnetic dT-CPG from Example VIII was packed in a DNA reaction column. The column was placed in the DNA synthesizer of model 381A manufactured by Applied Biosystems, Inc. (ABI). β -cyanoethyl phosphoramidites and other synthetic reagents for synthesis were acquired from ABI. A 20 mer oligonucleotide of the following sequence was synthesized, i.e., AGA/CAG/TCT/GAT/CTC/GAT/CT. The DMTr groups, which were removed in each synthesis cycle, were collected and measured at 504 nm to check for coupling efficiency. The 20 mers were then cleaved off from the solid phase and subjected to HPLC analysis. The results were found to be the same as those generated from regular non-magnetic glass particles.

EXAMPLE X

Synthesis of Non-Cleavable 25-Mer Oligonucleotide
With Magnetic Controlled Pore Glass
(Magnetic Oligonucleotide CPG)

1 gram of magnetic epoxy CPG from Example V was hydrolized in 10 ml of acidic aqueous solution at pH=4.0 (adjusted with hydrochloric acid) and at 40°C for two hours. At the end of reaction, the magnetic CPG was washed five time with 50 ml deionized water, because the epoxy group was converted into dihydroxyl group. This material was designed as magnetic glyceryl glass (magnetic glyceryl-CPG). 10 mg of this material was then packed in a DNA synthesis column. The column was placed in the automatic DNA synthesizer of model 381A manufactured by Applied Biosystems Inc. Beta-cyanoethyl phosphoramidites and

-16-

other reagents for synthesis were acquired from the same company. A 25-mer of deoxythymidine oligonucleotide of the following sequence was synthesized, i.e., TTT/TTT/TTT/TTT/TTT/TTT/TTT/TTT/T. The magnetic glass powder bearing the 25-mer was then subjected to the treatment of ammonium hydroxide to remove the phosphate protective groups. Due to the more stable phosphodiester linkage between the 25-mer oligonucleotide chain and the glass, a large fraction of the oligonucleotides remained covalently linked to the magnetic glass as confirmed by the DMTr groups and by the capability of the product to hybridize poly(dA)₁₂ oligonucleotides. Products bearing the 25-mer are useful to purify mRNA and poly(dA) immediately after synthesis. It is also useful in DNA assays. The magnetic glass with non-cleavable synthetic oligonucleotides is also useful in DNA assay.

EXAMPLE XI

Preparation of Protein A Coated Magnetic Controlled Pore Glass (Magnetic Protein A CPG) Useful as an Antibody Adsorbent

One gram of the product of example V (magnetic epoxy CPG) was placed in a vial containing 5 ml of 0.1 M sodium periodate aqueous solution. The vial was placed on a shaker and shook for 1 hour. At the end of reaction, the glass was washed with 5 X 5 ml deionized water. 15 mg of Protein A was dissolved in 5 ml of 0.01 M phosphate buffer of pH=7.2 and added to the glass. The vial was shaken gently in the refrigerator for 24 hours. At the end of coupling reaction, 0.02% (wt%) of sodium borohydride was added to the mixture, and the reaction was allowed to proceed for another two hours. pH was adjusted to around pH=8.5 to 9.0 with dilute hydrochloric acid or

-17-

sodium hydroxide if necessary. At the end of the reaction, the glass was washed 5 X 10 ml of phosphate buffer. The product was magnetic glass coated with Protein A.

200 mg of the Protein A magnetic glass was placed in a 8 ml vial which contained 5 ml of 10 mg goat anti-BSA (bovine serum albumin) antibody in 0.05 M phosphate buffer + 0.15 M sodium chloride of pH=7.5. The vial was then shook gently in the shaker for one half hour at room temperature. The glass was then washed with 5 X 5 ml of the loading buffer to remove the excess or unbound proteins. To elute the absorbed antibody from the Protein A magnetic glass, 3 X 1 ml of 0.1 M glycine/HCl buffer of pH=2.0 was used. The washing buffers were pooled together and the protein concentration was measured by Lowry's method at 280 nm. The Protein A magnetic glass was thus found to have a binding capacity of 8 mg goat anti-BSA (bovine serum albumin) antibody per gram of magnetic Protein A CPG.

-18-

CLAIMS:

1. Magnetic porous inorganic siliceous material having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.
2. Magnetic porous inorganic siliceous material as defined by claim 1 in which said magnetic particles are iron oxide particles.
3. Porous magnetic glass, silica gel or alumina having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.
4. Porous magnetic glass, silica gel or alumina as defined by claim 3 in which particles are iron oxide particles.
5. Porous inorganic siliceous material as defined by claim 1 having a surface to which a biological moiety may be attached.
6. Porous inorganic siliceous material as defined by claim 1 having a surface to which a biological moiety may be attached chemically or physically.
7. Porous inorganic siliceous material as defined by claim 6 in which said biological moiety is a molecule, an enzyme, an antibody, an antigen, an oligopeptide, an oligonucleotide, an oligosaccharide or a cell.
8. Magnetic porous inorganic siliceous material as defined by claim 1 having a surface bearing functional groups.

-19-

9. A magnetic porous, inorganic siliceous material as defined by claim 1 having a surface bearing amino, hydroxyl, carboxyl, epoxy, aldehyde, phenyl or long chain alkyl groups.

10. A magnetic, porous, inorganic material as defined by claim 1 having a surface bearing a nucleoside.

11. A biological moiety bound to a magnetic controlled pore glass support, said support having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.

12. A biological molecule, a cell, an antibody, an antigen, an oligopeptide, an oligonucleotide or an oligosaccharide bound to a magnetic controlled pore glass support, said support having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.

13. A process for producing a magnetic porous siliceous material as defined by claim 1 which comprises:

(i) mixing a porous siliceous particle having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, with colloidal magnetic particle for at least about 50 to 500 Angstrom;

(ii) separating said particle from said colloidal;

(iii) washing the separated particles; and

(iv) drying the separated and washed particle.

-20-

14. A process as defined by claim 13 in which said washing step (iii) includes an initial washing with water followed by washing with a polar liquid.

15. A process as defined by claim 14 in which said polar liquid is aqueous sodium chloride, acetone or methanol.

16. A process as defined by claim 13 or claim 14 in which said drying step (iv) is accomplished overnight at about 90°C or at about 120°C for one hour or by vacuum drying.

17. A process as defined by claim 13 in which said colloidal magnetic particles are in the form of a colloidal suspension of magnetic or superparamagnetic iron oxide particles in an aqueous or an organic medium.

18. A process as defined by claim 13 also comprising:

(v) silanization of said dried particles.

19. A method as defined by claim 18 in which the silicone compound used in said silanization step (v) has the formula $R-Si-X$ in which R represents an organic moiety with a terminal functional group such as an amino, hydroxyl, epoxy, aldehyde, sulfhydryl, phenyl, long chain alkyl or other group that will chemically react or physically absorb with the biological molecules and X may be a mono-, di- or trialkoxy or halide group which will react with the silanol groups on the surface of the inorganic material.

20. In a process for the synthesis of an oligonucleotide in which a nucleoside bound to a solid support is utilized, the improvement which comprises utilizing as said solid support a magnetic, porous inorganic material as defined by claim 1.

21. A process as defined by claim 20 in which said magnetic porous inorganic material is magnetic controlled pore glass.

-21-

22. In a process for synthesizing a peptide in which additional amino acid residues are added, an amino acid residue bound to the solid support, the improvement which comprises utilizing as said solid support magnetic controlled pore glass having an amino acid residue covalently attached thereto, said controlled pore glass having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.

AMENDED CLAIMS

[received by the International Bureau on 26 April 1993 (26.04.93);
original claims 1-21 deleted; original claim 22 renumbered as claim 1;
new claims 2-24 added; (5 pages)]

1. In a process for synthesizing a peptide in which additional amino acid residues are added, an amino acid residue bound to the solid support, the improvement which comprises utilizing as said solid support magnetic controlled pore glass having an amino acid residue covalently attached thereto, said controlled pore glass having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, said pores containing magnetic particles.

2. Particulate magnetic porous glass having
(i) a particle size of from about 1 to about 200 microns;

(ii) an original pore diameter of about 60 to about 6,000 Angstroms;

(iii) an original pore volume of about 0.5 to about 2.5 cc/gm; and

(iv) magnetic particles contained in and adsorbed on the surfaces of said pores.

3. Particulate magnetic porous glass having magnetic particles adsorbed on the surfaces of and contained in said pores.

4. Particulate magnetic porous glass as defined by claim 2 in which said siliceous material is glass or silica gel.

5. Particulate magnetic porous glass as defined by claims 2, 3 or 4 in which said magnetic particles are iron oxide particles.

6. Particulate magnetic porous glass as defined by by claims 2, 3 or 4 in which said magnetic particles are colloidal iron oxide particles.

7. Particulate magnetic porous glass in which the original pore volume is reduced by about 5% to about 15% by magnetic particles.

8. Particulate magnetic porous glass having

(i) a particle size of from about 1 to about 200 microns;

(ii) pores have a pore diameter of about 60 to about 6,000 Angstroms and a volume of about 0.5 to about 2.5 cc/gm;

(iii) magnetic particles contained in and adsorbed on the surfaces of said pores; and

(iv) a surface to which a biological molecule or a cell may be attached.

9. Particulate magnetic porous glass having magnetic particles adsorbed on the surfaces of and contained in said pores.

10. A particulate magnetic porous glass as defined by claim 8 in which said biological molecule is an enzyme, an antibody, an antigen, a nucleoside, an oligonucleotide, a peptide or an oligosaccharide.

11. Particulate magnetic porous glass having

(i) a particle size of from about 1 to about 200 microns;

(ii) pores having a diameter of about 60 to about 6,000 Angstroms and a pore volume of about 0.5 to about 2.5 cc/gm;

(iii) magnetic particles adsorbed on the surfaces of said pores; and

(iv) an external surface bearing functional groups to chemically bind biological molecules or cells thereto.

12. Particulate magnetic porous glass as defined by claim 11 in which said functional groups are an amino, hydroxyl, carboxyl, epoxy, aldehyde, phenyl or alkyl groups.

13. A biological molecule or a cell bound to a magnetic controlled pore glass support, said support having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a volume of from about 0.5 to about 2.5 cc/gm, said pores having magnetic particles adsorbed on the surface thereof.

14. The invention as defined by claim 13 in which said biological molecule is an antibody, an antigen, a peptide, a nucleoside, an oligonucleotide or an oligosaccharide.

15. A process for producing magnetic porous glass which comprises:

(i) mixing porous glass particles having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, with colloidal magnetic particles about 50 to 500 Angstroms in size;

(ii) thereafter separating said porous glass from said colloidal magnetic particles; and

(iii) washing and drying said separated particles.

16. A process for producing a magnetic controlled pore glass which comprises:

(i) mixing controlled pore glass particles having a particle size of from about 1 to about 200 microns, and pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, with colloidal magnetic particles about 50 to 500 Angstroms in size;

(ii) thereafter separating said controlled pore glass particles from said colloidal magnetic particles; and

(iii) washing and drying said separated particles.

17. A process as defined by claim 15 or 16 in which said washing step (iii) includes an initial washing with water followed by washing with a polar liquid.

18. A process as defined by claim 15 or claim 16 in which said washing step (iii) includes an initial washing with water followed by washing with aqueous sodium chloride, acetone or methanol.

19. A process as defined by claim 15 or claim 16 in which said drying in step (iii) is accomplished at a temperature of from about 90°C to 100°C for one hour or by overnight vacuum drying.

20. A process as defined by claim 15 or claim 16 in which said colloidal magnetic particles are in the form of a colloidal suspension of magnetic or superparamagnetic iron oxide particles in an aqueous or an organic medium.

21. Magnetic porous glass produced by the process of

(i) mixing porous glass particles having a particle size of from about 1 to about 200 microns, pores having a diameter of from about 60 to about 6,000 Angstroms and a pore volume of from about 0.5 to about 2.5 cc/gm, with 50 to 500 Angstrom colloidal magnetic particles;

(ii) separating said siliceous particles from said colloidal magnetic particles; and

(iii) washing and thereafter drying said separated magnetic siliceous particles.

22. A magnetic porous glass as defined by claim 21 in which said process includes the step of
(iv) silanizing said dried magnetic glass particles.

23. A process as defined by claim 22 in which said silanization is accomplished with a silicone compound, said compound having the formula $R-Si-X$ in which R represents an organic moiety with a terminal functional group that will chemically react or physically absorb with the biological molecules and X is a mono-, di- or trialkoxy or halide group which will react with the silanol groups on the surface of the inorganic material.

24. In a process for the synthesis of an oligonucleotide in which a nucleoside bound to a solid support is utilized, the improvement which comprises utilizing as said solid support a magnetic, porous glass as defined by claim 11.

INTERNATIONAL SEARCH REPORT

PCT/US92/10113

A. CLASSIFICATION OF SUBJECT MATTER IPC(5) :C08F 283/00; C03C 4/00, 15/00 US CL :Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 525/54.11; 530/334; 536/22; 252/62.51,62.56,62.58,62.59; 428/402,404,405,406 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X	US,A, 4,233,169 (Beall et al.) 11 November 1980 See Abstract, Col. 2, lines 5-37, Col. 4, lines 20-28, Col. 5, lines 41-46, Col. 10, lines 63-69, Col. 16, lines 7-10.	1-7,20,21																		
Y	US,A, 4,812,512 (Buendia et al.) 14 March 1989 See Abstract, Col. 2, lines 44-47, 63-69, Col. 3, lines 59 and 60.	1-12,20,21																		
Y	US,A, 3,042,543 (Schuele) 03 July 1962 See Col. 1, lines 60-70.	13-19																		
Y	US,A, 4,631,211 (Houghten) 23 December 1986 See the entire document.	1-12,20-22																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A* document defining the general state of the art which is not considered to be part of particular relevance</td><td>*X*</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*E* earlier document published on or after the international filing date</td><td>*Y*</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*Z*</td><td>document member of the same patent family</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td></td><td></td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 25 JANUARY 1993		Date of mailing of the international search report 17 FEB 1993																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE		Authorized officer <i>J. Cooper</i> J. COOPER Telephone No. (703) 308-2511																		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/10113

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	-Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A, 5,037,882 (Steel) 06 August 1991 See the entire document.	1-12,20-22
Y,P	US,A, 5,141,813 (Nelson) 25 August 1992 See the entire document.	1-12,20,21
X,P	US,A, 5,128,204 (Charmot) 07 July 1992 See the entire document.	1-12,20-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/10113

A. CLASSIFICATION OF SUBJECT MATTER:

US CL : -

525/54.11; 530/334; 536/22; 252/62.51,62.56,62.58,62.59; 428/402,404,405,406